{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "MOTS-c has measurable metabolic and functional effects in rodent models; benefit from administering native MOTS-c to humans for healthspan remains unestablished.",
  "implications": "Overall Γ follows preregistered primary human-administered SC3. Partial native molecular SC1 is Γ and explicitly scoped rodent metabolic/functional pharmacology SC2 is Ε under a declared phenotype adaptation. Controlled model benefit is retained; neither endogenous exercise-marker induction, K14Q population association nor an analogue program supplies native human healthspan causality.",
  "limitations": "64 primary reports with 7 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}